Emideltide (DSIP): What It Is and Why the FDA Reviewed It in 2026
If you started seeing the word emideltide in FDA news this month, it is not a new peptide. Emideltide is the label the FDA uses for DSIP, the delta sleep-inducing peptide that has circulated in sleep and recovery research for decades. It landed in the headlines because it was on the agenda at the FDA compounding advisory meeting on July 24, 2026. This page explains what emideltide is, why the two names refer to the same molecule, what it has been studied for, and what the review does and does not change.
What Is Emideltide?
Emideltide is a nine-amino-acid neuropeptide first isolated from rabbit brain in the 1970s by researchers studying sleep. Its original name, delta sleep-inducing peptide, came from the observation that it promoted delta-wave activity, the slow brain waves of deep sleep. The peptide is small, crosses into the nervous system, and has been investigated as a signaling molecule involved in sleep regulation and stress responses.
The emideltide name is the one that appears in FDA compounding paperwork. For the broader research history and the reported dosing under its common name, see our DSIP peptide guide.
Emideltide vs DSIP: Same Molecule, Two Names
There is no chemical difference between emideltide and DSIP. Emideltide is a formal naming used in regulatory and pharmaceutical contexts; DSIP is the descriptive name used across most of the scientific literature and in the peptide community. When the FDA briefing documents and news coverage say emideltide, they mean the delta sleep-inducing peptide. The double naming is why the term looked unfamiliar even to people who already knew DSIP.
The July 2026 FDA Compounding Review
Emideltide was one of seven peptides the FDA Pharmacy Compounding Advisory Committee took up on July 23-24, 2026. It was on day two, July 24, together with Semax and Epitalon. Day one covered BPC-157, KPV, TB-500, and MOTS-c.
The committee decides whether to recommend a substance for the 503A bulks list, which is what allows traditional compounding pharmacies to make a drug from bulk powder for individual patients. The emideltide nomination lists intended uses of opioid withdrawal, chronic insomnia, and narcolepsy. Before the meeting, FDA career scientists posted materials recommending against adding any of the seven peptides, citing thin safety and effectiveness evidence.
A committee vote is advisory only. Even a favorable vote would not immediately make emideltide compoundable, because the FDA has to run a separate rulemaking to change the list. For the full agenda, the evidence under review, and how to read the outcome, see our PCAC hearing guide.
Result — July 24, 2026. The committee voted 6-7, with one abstention, against recommending emideltide for the 503A bulks list. It was the only one of the seven peptides the panel rejected; the other six, including Semax and Epitalon on the same day, were recommended. Emideltide stays off the compounding pathway, so nothing changes for its legal status.
How Emideltide Is Thought to Work
The mechanism is not fully settled. DSIP appears to interact with sleep-regulating and stress-regulating systems in the brain, including effects on the hypothalamic-pituitary axis and on neurotransmitter signaling tied to arousal. It is not a sedative in the way a sleeping pill is; the research framing is more about modulating the systems that govern deep sleep and stress than about forcing sedation. Because the early work is decades old and used varied methods, the picture remains incomplete.
What It Has Been Studied For
Three threads dominate: sleep, stress, and withdrawal. The sleep interest is the oldest, tied to the peptide's name and its delta-wave effects in animals. Stress research looked at whether DSIP could blunt physiological stress responses. The withdrawal angle, reflected in the FDA nomination, examined whether it could ease opioid and alcohol withdrawal symptoms.
Across all three, the human data are limited and mixed, which is part of why FDA reviewers were cautious. If your interest is specifically sleep, the DSIP guide covers the reported protocols, and our Semax vs Selank comparison is useful if you are weighing neuropeptides more broadly.
Dosage and Sourcing Notes
There is no approved dose. Because emideltide is not on the 503A bulks list, compounding pharmacies generally cannot dispense it, so most supply is research-grade powder labeled for laboratory use only. That puts purity, sterility, and dose accuracy on the buyer. Our guide on where to buy peptides explains how to evaluate a certificate of analysis, and the reconstitution guide covers mixing lyophilized peptide if you are researching the injectable form.
Bottom Line
Emideltide is DSIP under a different name, pulled into the news by the July 2026 FDA compounding review. It has a long but thin research record in sleep, stress, and withdrawal, and it is neither approved nor currently compoundable. Treat the two names as interchangeable, treat the dosing figures as estimates, and follow the PCAC outcome if you want to know whether a legal compounding pathway opens.
Frequently Asked Questions About Emideltide (DSIP)
Emideltide is a name used for delta sleep-inducing peptide (DSIP), a small nine-amino-acid neuropeptide first isolated from the brain in the 1970s. It appears in FDA compounding documents under the emideltide label. It is studied for sleep, stress resilience, and opioid withdrawal, but it is not an FDA-approved drug.
Yes. Emideltide is the naming the FDA and its advisory committee use for the delta sleep-inducing peptide most people know as DSIP. If you have read about DSIP for sleep, that is the same molecule. Our DSIP peptide guide covers the research and dosing under the more common name.
Emideltide (DSIP) was one of three peptides on day two of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 24, 2026, alongside Semax and Epitalon. The committee evaluates whether bulk substances should be added to the 503A list that lets compounding pharmacies make them. The nomination listed emideltide for opioid withdrawal, chronic insomnia, and narcolepsy. FDA staff recommended against it, and on July 24, 2026 the committee agreed, voting 6-7 against recommending it, the only rejection among the seven peptides reviewed.
Research interest centers on sleep, where DSIP was named for its ability to promote delta-wave (deep) sleep in early animal studies. It has also been studied for stress and for easing opioid and alcohol withdrawal symptoms. The human evidence is old and limited, and results have been inconsistent, so these uses remain investigational.
It is not FDA-approved, and as of the July 2026 review it is not on the 503A bulks list, so compounding pharmacies generally cannot make it for patients. Most material circulates as research-grade powder labeled for laboratory use only. The PCAC review could change the compounding pathway, but only through a formal FDA rulemaking that has not happened. See our peptide legality guide for context.
Reported effects in the limited literature are generally mild, but controlled human safety data are scarce because most studies are decades old and small. As with other research-grade peptides, purity and dosing accuracy are practical concerns. Anyone considering it should involve a licensed clinician rather than self-experiment.